CTOs on the Move

OmniSonics Medical Technologies

www.omnisonics.com

 
At OmniSonics, we are a team of highly dedicated people focused on building technology that will allow physicians to improve the quality of life for patients suffering from vascular diseases - such as deep vein thrombosis (DVT) and peripheral arterial
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

PetDx

PetDx® – The Liquid Biopsy Company for Pets™ is a molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health.

Brooks Rehabilitation

Our foundation supports many programs throughout the Brooks System of Care, including clinical research, adaptive sports and wellness, school re-entry, and free care for those who need it most. Our Volunteer Services department provides an opportunity for personal growth, education, and service to others. Our goal is to meet the needs of our volunteers while carrying out our vision of providing world-class service to our patients. Volunteer assignments are made according to interest, availability, and the skills needed to fulfill task requirements.

Xealth

Xealth enables healthcare teams to order digital content and services as easily as they do medications today.

The Community Health Network of Connecticut Foundation

The Community Health Network of Connecticut Foundation is a Wallingford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.